

1. Bulfamante, G., Bocci, T., Falleni, M., Campiglio, L., Coppola, S., Tosi, D., ... & Chiumello, D. (2022). Brainstem neuropathology in COVID-19: Evidence for SARS-CoV-2 neurotropism and microglial activation. *Frontiers in Neurology*, 13, 834456.
2. Castañeyra-Perdomo, A., et al. (2024). A narrative review on the clinical relevance of imaging the circumventricular brain organs and performing their anatomical and histopathological examination in acute and postacute COVID-19. *Frontiers in Neuroanatomy*, 18, 102–121.
3. Chaganti, V., et al. (2025). Asymmetrical glymphatic dysfunction in patients with long COVID. *BMC Neurology*, 25(3), 451–466
4. Davis, C. M. (2017). *Integrative therapies in rehabilitation: Evidence for efficacy in therapy, prevention, and wellness* (4th ed.). Thorofare, NJ: SLACK Incorporated.
5. Hablitz, L. M., et al. (2020). Circadian control of brain glymphatic and lymphatic fluid flow. *Nature Communications*, 11, 4411.
6. Heald, A. H., Perrin, R. N., Walther, A., Stedman, M., Hanna, M., Mukherjee, A., & Riste, L. (2022). Reducing fatigue-related symptoms in Long COVID-19: A preliminary report of a lymphatic drainage intervention. *Cardiovascular Endocrinology & Metabolism*, 11(2), e0261.
7. Iliff, J. J., et al. (2012). A paravascular pathway facilitates cerebrospinal fluid flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. *Science Translational Medicine*, 4(147), 147ra111.
8. Kanjwal, K., Jamal, S., Kichloo, A., & Grubb, B. P. (2022). Dysautonomia in COVID-19 patients: A narrative review on clinical and pathophysiological evidence. *Frontiers in Neurology*, 13, 9198643.
9. Lou, J. J., Movassaghi, M., Gordy, D., Olson, M. G., Zhang, T., Khurana, M. S., & Koralnik, I. J. (2021). Neuropathology of COVID-19: Mechanisms underlying neurological complications in SARS-CoV-2 infection. *Frontiers in Neurology*, 12, 621993.
10. Matschke, J., Lütgehetmann, M., Hagel, C., Sperhake, J. P., Schröder, A. S., Edler, C., ... & Püschel, K. (2020). Neuropathology of patients with COVID-19 in Germany: A post-mortem case series. *The Lancet Neurology*, 19(11), 919–929.
11. Meinhardt, J., Radke, J., Dittmayer, C., et al. (2021). Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system

entry in individuals with COVID-19. *Nature Neuroscience*, 24(2), 168–175.

12. Mestre, H., et al. (2018). Aquaporin-4-dependent glymphatic solute transport in the rodent brain. *eLife*, 7, e40070.

13. Nedergaard, M., & Goldman, S. A. (2020). Brain fluids and glymphatic system: Regulation, function, and therapeutic implications. *Physiological Reviews*, 100(2), 963–1003.

14. Springer Immunology. (2025). Dysautonomia: A common comorbidity of systemic disease. *Journal of Neuroimmunology and Inflammation*, 38(1), 1–14.

15. Timmerman, H. (2023). De Epiphora-methode: herstel van doorbloeding en zenuwbalans door houding en ademhaling. *Adem & Bewustzijn Journal*, 7(2), 34–41.

16. Wenzel, J., Lampe, J., Müller-Fielitz, H., Schuster, R., Zille, M., Müller, K., ... & Endres, M. (2021). The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. *Nature Neuroscience*, 24(11), 1522–1533.

17. Hokyung, J., et al (2025). Increased CSF drainage by non-invasive manipulation of cervical lymphatics. *Nature*, vol. 643, 755–767